Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) signed an agreement to acquire HyTest Ltd. from Summa Equity for approximately €550 million on May 15, 2021. The transaction is subject to customary regulatory and antitrust approvals. Completion of the transaction is expected in the second half of the year 2021. The transaction has been approved unanimously with the board of directors of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. The transaction will be funded by the Company’s own cash or the short-term bridge loans obtained by MR Global. Andrew Huntley, Anthony Siu and Simeng Zhang of BDA Partners and William Blair acted as financial advisors and Avance Attorneys Ltd. acted as legal advisor to HyTest. Lazard Ltd acted as financial advisor to Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) completed the acquisition of HyTest Ltd. from Summa Equity on September 22, 2021.